The esketamine EEG-microstate finding is not independently replicated in a controlled cohort within 12 weeks; claims stay preliminary.

Predicted 2026-07-24 · Resolves 2026-10-16 · research · Global

70%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

Researchers found that esketamine (a prescription ketamine-based drug) changed specific brain wave patterns within 24 hours in people with severe depression. That's interesting, but confirming it requires other labs running the same test on different patients — and that kind of independent check takes much longer than 12 weeks to design, run, and publish.

Resolution rule: YES if, by 2026-10-16, no peer-reviewed publication or preprint (checked via PubMed and medRxiv/bioRxiv searches for 'esketamine EEG microstate') reports independent replication of the 24h EEG-microstate finding in a controlled cohort (i.e., with a comparison/placebo arm). If such a controlled replication appears, resolves NO.

Rapid 24h biomarkers need controlled replication. The mechanistic story is compelling but the translational leap is being rushed. Independent replication in an adequately-powered controlled cohort within 12 weeks is unrealistic for a novel EEG-microstate biomarker.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →